{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T08:12:41Z","timestamp":1788336761598,"version":"build-2803163510"},"reference-count":52,"publisher":"American Association for Cancer Research (AACR)","issue":"17","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2119"],"award-info":[{"award-number":["CC2119"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2097"],"award-info":[{"award-number":["CC2097"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["CC2119"],"award-info":[{"award-number":["CC2119"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2097"],"award-info":[{"award-number":["CC2097"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["CC2119"],"award-info":[{"award-number":["CC2119"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["RASImmune"],"award-info":[{"award-number":["RASImmune"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019364","name":"Revolution Medicines","doi-asserted-by":"publisher","award":["CRA"],"award-info":[{"award-number":["CRA"]}],"id":[{"id":"10.13039\/100019364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CC2097"],"award-info":[{"award-number":["CC2097"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>The clinical benefit of therapies targeting the KRAS G12C mutation is substantially limited by the development of resistance through multiple mechanisms. Therefore, to achieve lasting benefit with these therapies, effective strategies to tackle the evolution of drug resistance are required. To investigate this, we developed a preclinical model that mimics the development of resistance to KRAS G12C inhibitors (G12Ci), such as adagrasib and RMC-4998. Treatment of tumors containing a minor subpopulation of resistant cancer cells with G12Ci led to their rapid outgrowth, replacing drug-sensitive cells within a few weeks. However, combining G12Ci with therapies that enhance immune responses, such as anti\u2013PD-1 or SHP2 inhibitors, resulted in the elimination of resistant cells and durable complete responses, even though anti-PD-1 or SHP2 inhibitor monotherapy did not induce regression of resistant tumors in the absence of drug-sensitive cells. This bystander killing of resistant cells following targeting of drug-sensitive cells was dependent on an intact adaptive immune system. Mechanistically, these combination therapies led to profound remodeling of the tumor immune microenvironment, making it less immunosuppressive, and promoted cancer cell death that primed an immune response, with an influx of cytotoxic T lymphocytes recognizing tumor-associated antigens shared between G12Ci-resistant and -sensitive cancer cells. Promotion of immune-mediated bystander elimination of drug-resistant cells may provide a paradigm for tackling the problem of drug resistance in cancer more broadly.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Combination therapies that stimulate antitumor immunity promote immune-mediated bystander killing of KRAS-G12C inhibitor resistant subpopulations, providing a strategy to overcome drug resistance that might have relevance in broader therapeutic settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-25-5693","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:38:49Z","timestamp":1780947529000},"page":"4334-4351","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["KRAS Inhibitor\u2013Induced Cancer Cell Death Enhances Sensitivity to Immune-Mediated Bystander Killing of Drug-Resistant Subclones"],"prefix":"10.1158","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1656-3326","authenticated-orcid":false,"given":"Mona","family":"Tomaschko","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2384-7777","authenticated-orcid":false,"given":"KangBo","family":"Ng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 2 Polarity and Patterning Networks Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4653-1427","authenticated-orcid":false,"given":"Christopher","family":"Moore","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-6198","authenticated-orcid":false,"given":"Claire E.","family":"Pillsbury","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3544-4184","authenticated-orcid":false,"given":"Sareena","family":"Rana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-8766","authenticated-orcid":false,"given":"James","family":"Campbell","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 3 Bioinformatics and Biostatistics, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8704-481X","authenticated-orcid":false,"given":"Saptaparna","family":"Mukherjee","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0603-6867","authenticated-orcid":false,"given":"Anna","family":"Mikolajczak","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 4 Experimental Histopathology, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9894-0537","authenticated-orcid":false,"given":"Panayiotis","family":"Anastasiou","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7225-2078","authenticated-orcid":false,"given":"Andrea","family":"de Castro","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4898-6871","authenticated-orcid":false,"given":"Alicia","family":"Alonso de la Vega","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9341-2586","authenticated-orcid":false,"given":"Sophie","family":"de Carn\u00e9 Tr\u00e9cesson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8710-4467","authenticated-orcid":false,"given":"Nathan W.","family":"Goehring","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 2 Polarity and Patterning Networks Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8176-8948","authenticated-orcid":false,"given":"Miriam","family":"Molina-Arcas","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2331-4729","authenticated-orcid":false,"given":"Julian","family":"Downward","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04tnbqb63","id-type":"ROR","asserted-by":"publisher"}],"name":"The Francis Crick Institute 1 Oncogene Biology Laboratory, , London, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026090203141661200_bib1","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"2026090203141661200_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2026090203141661200_bib3","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat Commun"},{"key":"2026090203141661200_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"2026090203141661200_bib5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"key":"2026090203141661200_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"2026090203141661200_bib7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"2026090203141661200_bib8","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090203141661200_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(23)00221-0","article-title":"Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial","volume":"401","author":"de Langen","year":"2023","journal-title":"Lancet"},{"key":"2026090203141661200_bib10","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1126\/science.adg9652","article-title":"Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS","volume":"381","author":"Schulze","year":"2023","journal-title":"Science"},{"key":"2026090203141661200_bib11","doi-asserted-by":"crossref","first-page":"PR014","DOI":"10.1158\/1535-7163.TARG-23-PR014","article-title":"Abstract PR014: preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C (ON) inhibitor, in patients with or without prior KRASG12C (OFF) inhibitor treatment","volume":"22","author":"J\u00e4nne","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2026090203141661200_bib12","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1038\/s41598-022-06369-3","article-title":"Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition","volume":"12","author":"Vaclova","year":"2022","journal-title":"Sci Rep"},{"key":"2026090203141661200_bib13","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRASG12C inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N Engl J Med"},{"key":"2026090203141661200_bib14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.annonc.2025.01.020","article-title":"Genomic landscape of clinically acquired resistance alterations in patients treated with KRASG12C inhibitors","volume":"36","author":"Riedl","year":"2025","journal-title":"Ann Oncol"},{"key":"2026090203141661200_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"2026090203141661200_bib16","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1158\/1078-0432.CCR-19-3523","article-title":"Vertical pathway inhibition overcomes adaptive feedback resistance to KRAS(G12C) inhibition","volume":"26","author":"Ryan","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026090203141661200_bib17","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-20-2077","article-title":"Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer","volume":"26","author":"Adachi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026090203141661200_bib18","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s43018-023-00577-0","article-title":"An allosteric pan-TEAD inhibitor blocks oncogenic YAP\/TAZ signaling and overcomes KRAS G12C inhibitor resistance","volume":"4","author":"Hagenbeek","year":"2023","journal-title":"Nat Cancer"},{"key":"2026090203141661200_bib19","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/cas.16441","article-title":"Mechanisms of resistance to KRAS inhibitors: cancer cells\u2019 strategic use of normal cellular mechanisms to adapt","volume":"116","author":"Tanaka","year":"2025","journal-title":"Cancer Sci"},{"key":"2026090203141661200_bib20","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1158\/2159-8290.CD-25-0349","article-title":"Response and resistance to RAS inhibition in cancer","volume":"15","author":"Ebright","year":"2025","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib21","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1158\/1078-0432.CCR-25-0821","article-title":"KRAS inhibitors in pancreas cancer: facts and hopes about the immunotherapy we have all been waiting for","volume":"32","author":"Stanger","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026090203141661200_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2026090203141661200_bib23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","article-title":"The KRAS(G12C) inhibitor MRTX849 reconditions the tumor immune microenvironment and sensitizes tumors to checkpoint inhibitor therapy","volume":"20","author":"Briere","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2026090203141661200_bib24","doi-asserted-by":"crossref","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","article-title":"Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers","volume":"8","author":"Mugarza","year":"2022","journal-title":"Sci Adv"},{"key":"2026090203141661200_bib25","doi-asserted-by":"crossref","first-page":"e153470","DOI":"10.1172\/JCI153470","article-title":"Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47","volume":"133","author":"Hu","year":"2023","journal-title":"J Clin Invest"},{"key":"2026090203141661200_bib26","doi-asserted-by":"crossref","first-page":"5906","DOI":"10.1038\/s41467-021-26214-x","article-title":"Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry","volume":"12","author":"van Maldegem","year":"2021","journal-title":"Nat Commun"},{"key":"2026090203141661200_bib27","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","article-title":"KRASG12D inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8+ T cells","volume":"41","author":"Mahadevan","year":"2023","journal-title":"Cancer Cell"},{"key":"2026090203141661200_bib28","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1158\/0008-5472.CAN-22-0325","article-title":"An immunogenic model of KRAS-mutant lung cancer enables evaluation of targeted therapy and immunotherapy combinations","volume":"82","author":"Boumelha","year":"2022","journal-title":"Cancer Res"},{"key":"2026090203141661200_bib29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","article-title":"Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer","volume":"13","author":"Kemp","year":"2023","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3390\/jcm9051362","article-title":"Immune checkpoint inhibitors for lung cancer treatment: a review","volume":"9","author":"Onoi","year":"2020","journal-title":"J Clin Med"},{"key":"2026090203141661200_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3892\/mco.2024.2730","article-title":"Clinical predictors of response to single-agent immune checkpoint inhibitors in chemotherapy-pretreated non-small cell lung cancer","volume":"20","author":"Musaelyan","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"2026090203141661200_bib32","doi-asserted-by":"crossref","first-page":"8146","DOI":"10.1038\/s41467-024-52324-3","article-title":"Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade","volume":"15","author":"Anastasiou","year":"2024","journal-title":"Nat Commun"},{"key":"2026090203141661200_bib33","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1158\/0008-5472.CAN-19-3038","article-title":"Allosteric inhibition of SHP2 stimulates antitumor immunity by transforming the immunosuppressive environment","volume":"80","author":"Quintana","year":"2020","journal-title":"Cancer Res"},{"key":"2026090203141661200_bib34","doi-asserted-by":"crossref","first-page":"e20201414","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J Exp Med"},{"key":"2026090203141661200_bib35","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: first report of safety\/efficacy of sotorasib in combination with pembrolizumab or atezolizumab in advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J Thorac Oncol"},{"key":"2026090203141661200_bib36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"2026090203141661200_bib37","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","article-title":"Targeting immunogenic cell stress and death for cancer therapy","volume":"23","author":"Galluzzi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"2026090203141661200_bib38","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1158\/0008-5472.CAN-23-2627","article-title":"CRISPR-Cas9 screening identifies KRAS-induced COX2 as a driver of immunotherapy resistance in lung cancer","volume":"84","author":"Boumelha","year":"2024","journal-title":"Cancer Res"},{"key":"2026090203141661200_bib39","doi-asserted-by":"crossref","first-page":"e109956","DOI":"10.1371\/journal.pone.0109956","article-title":"\u201cGlowing head\u201d mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts","volume":"9","author":"Day","year":"2014","journal-title":"PLoS One"},{"key":"2026090203141661200_bib40","first-page":"265","article-title":"Cell detection with star-convex polygons","author":"Schmidt","year":"2018"},{"key":"2026090203141661200_bib41","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.trecan.2017.08.006","article-title":"KRAS alleles: the devil is in the detail","volume":"3","author":"Haigis","year":"2017","journal-title":"Trends Cancer"},{"key":"2026090203141661200_bib42","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2159-8290.CD-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-19-1409","article-title":"Overcoming genetically based resistance mechanisms to PD-1 blockade","volume":"10","author":"Torrejon","year":"2020","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccr.2009.03.022","article-title":"A gene expression signature associated with \u201cK-Ras addiction\u201d reveals regulators of EMT and tumor cell survival","volume":"15","author":"Singh","year":"2009","journal-title":"Cancer Cell"},{"key":"2026090203141661200_bib45","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1158\/2159-8290.CD-24-0177","article-title":"Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer","volume":"14","author":"Dilly","year":"2024","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib46","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1158\/2159-8290.CD-15-1377","article-title":"Epithelial-to-mesenchymal transition defines feedback activation of receptor tyrosine kinase signaling induced by MEK inhibition in KRAS-mutant lung cancer","volume":"6","author":"Kitai","year":"2016","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib47","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1158\/1078-0432.CCR-20-3872","article-title":"Cell type-specific adaptive signaling responses to KRAS(G12C) inhibition","volume":"27","author":"Solanki","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026090203141661200_bib48","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"},{"key":"2026090203141661200_bib49","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2159-8290.CD-25-1616","article-title":"Abrogation of oncogenic RAS signaling by a RAS(ON) inhibitor doublet primes immune-refractory KRASG12C-mutant NSCLC for immune checkpoint blockade","volume":"16","author":"Wei","year":"2026","journal-title":"Cancer Discov"},{"key":"2026090203141661200_bib50","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.jtho.2023.05.013","article-title":"Brief report: severe sotorasib-related hepatotoxicity and non-liver adverse events associated with sequential anti\u2013programmed cell death (Ligand)1 and sotorasib therapy in KRASG12C-Mutant lung cancer","volume":"18","author":"Chour","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026090203141661200_bib51","doi-asserted-by":"crossref","first-page":"eadl6464","DOI":"10.1126\/sciadv.adl6464","article-title":"Spatial multiplex analysis of lung cancer reveals that regulatory T cells attenuate KRAS-G12C inhibitor-induced immune responses","volume":"10","author":"Cole","year":"2024","journal-title":"Sci Adv"},{"key":"2026090203141661200_bib52","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1158\/2159-8290.CD-24-0489","article-title":"Combined KRAS inhibition and immune therapy generates durable complete responses in an autochthonous PDAC model","volume":"15","author":"Liu","year":"2025","journal-title":"Cancer Discov"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-5693\/3802611\/can-25-5693.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-25-5693\/3809917\/can-25-5693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/17\/4334\/3823320\/can-25-5693.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/86\/17\/4334\/3823320\/can-25-5693.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T07:14:29Z","timestamp":1788333269000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/86\/17\/4334\/787519\/KRAS-Inhibitor-Induced-Cancer-Cell-Death-Enhances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":52,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,6,8]]},"published-print":{"date-parts":[[2026,9,2]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-25-5693","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.8688030","asserted-by":"object"}],"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.33414819","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414849","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414837","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414807","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414834","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414822","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414888","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414858","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414846","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414852","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414840","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414876","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414810","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414864","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414870","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414894","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414816","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414828","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414867","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414855","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414825","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414879","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414813","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414885","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414873","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414843","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414831","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414891","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.33414861","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]}}}